Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer

de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Colon/Rectal Cancer, 2015 ver.2. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp . Accessed 2 Dec 2016

Watanabe T, Itabashi M, Shimada Y et al (2015) Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol 20:207–239

Makrilia N, Syrigou E, Kaklamanos I et al (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. doi: 10.1155/2010/207084

Brandi G, Pantaleo MA, Galli C et al (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89:477–481

Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

Suenaga M, Mizunuma N, Shinozaki E et al (2008) Management of allergic reactions to oxaliplatin in colorectal cancer patients. J Support Oncol 6:373–378

Ichikawa Y, Goto A, Hirokawa S et al (2009) Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol 39:616–620

Shibata Y, Ariyama H, Baba E et al (2009) Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol 14:397–401

Mori Y, Nishimura T, Kitano T et al (2010) Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. Oncology 79:136–143

Shao YY, Hu FC, Liang JT et al (2010) Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc 109:362–368

Kidera Y, Satoh T, Ueda S et al (2011) High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 16:244–249

Seki K, Senzaki K, Tsuduki Y et al (2011) Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer. Int J Med Sci 8:210–215

Arii D, Ikeno Y, Murooka K et al (2012) Expression of allergic reactions to oxaliplatin. Jpn J Cancer Chemother 39:593–597

Yamauchi H, Goto T, Takayoshi K et al (2015) A retrospective analysis of the risk factors for allergic reactions induced by the administration of oxaliplatin. Eur J Cancer Care 24:111–116

Parel M, Ranchon F, Nosbaum A et al (2014) Hypersensitivity to oxaliplatin: clinical features and risk factors. BMC. Pharmacol Toxicol 15:1. http://www.biomedcentral.com/2050-6511/15/1

Park HJ, Lee JH, Kim SR et al (2016) A new practical desensitization protocol for oxaliplatin-induced immediate hypersensitivity reactions: a necessary and useful approach. J Investig Allergol Clin Immunol 26:168–176

Aroldi F, Prochilo T, Bertocchi P et al (2015) Oxaliplatin-induced hypersensitivity reaction: underlying mechanisms and management. J Chemther 27:63–66

Yoshida Y, Hirata K, Matsuoka H et al (2015) A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial. Drug Des Devel Ther 11:6067–6073

Sugihara K, Ohtsu A, Shimada Y et al (2012) Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four western studies. Clin Colorectal Cancer 11:127–137

Lee S, Kang H, Song W et al (2014) Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure. Cancer Chemther Pharmacol 73:1021–1029

Leguy-Seguin V, Jolimoy G, Coudert B et al (2007) Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 119:726–730

Lenz HJ (2007) Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601–609

Bano N, Najam R, Qazi F et al (2016) Clinical features of oxaliplatin induced hypersensitivity reactions and therapeutic approaches. Asian Pacific J Cancer Prevent 17:1637–1641

Iwamoto T, Yuta A, Tabata T et al (2012) Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull 35:1487–1495

Kitada N, Dan T, Takara K et al (2007) Oxaliplatin-induced hypersensitivity reaction displaying marked elevation of immunoglobulin E. J Oncol Pharm Pract 13:233–235

Syrigou E, Syrigos K, Saif MV et al (2008) Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 8:56–62

Yoshida Y, Hoshino S, Aisu N et al (2012) Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res 2:132–141